SV2003000928A - Conjugados de pregabalina-lactosa ref. pca513-01 - Google Patents
Conjugados de pregabalina-lactosa ref. pca513-01Info
- Publication number
- SV2003000928A SV2003000928A SV2002000928A SV2002000928A SV2003000928A SV 2003000928 A SV2003000928 A SV 2003000928A SV 2002000928 A SV2002000928 A SV 2002000928A SV 2002000928 A SV2002000928 A SV 2002000928A SV 2003000928 A SV2003000928 A SV 2003000928A
- Authority
- SV
- El Salvador
- Prior art keywords
- pregabaline
- pca513
- ref
- disorders
- subject
- Prior art date
Links
- 239000008101 lactose Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
DE ACUERDO CON LA PRESENTE INVENCION SE PROPORCIONA COMPUESTOS CONJUGADOS DE PREGABALINA-LACTOSA.TAMBIEN SE PROPORCIONA COMO PARTE DE LA PRESETEN INVENCION UN NUEVO METODO PARA TRATAR UN SUJETO TRASTORNOS O ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, QUE INCLUYE TRASTORNOS DE CRISIS CONVULSIVAS, DOLOR DEPRESION, ANSIEDAD, TRASTORNOS DEL SUEÑO, TRASTORNOS CONSUNTIVOS, PSICOSIS, DISCINESIA TARDIA, ENFERMEDAD DE HUNTINGTON O PARKINSON, ADMINISTRANDO AL SUJETO UNA CANTIDAD FARMACEUTICAMENTE EFICAZ DE UN CONJUGADO DE PREGABALINA LACTOSA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28017601P | 2001-03-30 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2003000928A true SV2003000928A (es) | 2003-07-29 |
Family
ID=23072002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2002000928A SV2003000928A (es) | 2001-03-30 | 2002-03-22 | Conjugados de pregabalina-lactosa ref. pca513-01 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7022678B2 (es) |
| EP (1) | EP1377318A2 (es) |
| JP (1) | JP2004524357A (es) |
| KR (1) | KR20040008146A (es) |
| CN (1) | CN1511043A (es) |
| AP (1) | AP2003002873A0 (es) |
| AR (1) | AR033024A1 (es) |
| BG (1) | BG108193A (es) |
| BR (1) | BR0208439A (es) |
| CA (1) | CA2440468C (es) |
| CZ (1) | CZ20032547A3 (es) |
| DO (1) | DOP2002000356A (es) |
| EA (1) | EA200300954A1 (es) |
| EC (1) | ECSP034740A (es) |
| EE (1) | EE200300480A (es) |
| GT (1) | GT200200051A (es) |
| HU (1) | HUP0303956A2 (es) |
| IL (1) | IL157879A0 (es) |
| IS (1) | IS6912A (es) |
| MA (1) | MA27004A1 (es) |
| MX (1) | MXPA03007437A (es) |
| NO (1) | NO20034348L (es) |
| OA (1) | OA12456A (es) |
| PA (1) | PA8542101A1 (es) |
| PE (1) | PE20021016A1 (es) |
| PL (1) | PL369179A1 (es) |
| SK (1) | SK11832003A3 (es) |
| SV (1) | SV2003000928A (es) |
| TN (1) | TNSN02038A1 (es) |
| UY (1) | UY27233A1 (es) |
| WO (1) | WO2002078747A2 (es) |
| ZA (1) | ZA200306608B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| EP1802568A1 (en) | 2005-09-19 | 2007-07-04 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin |
| DE102007019071A1 (de) * | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| WO2009158343A1 (en) * | 2008-06-23 | 2009-12-30 | Teva Pharmaceutical Industries, Ltd. | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010115612A2 (en) | 2009-04-10 | 2010-10-14 | Synthon B.V. | Pregabalin compositions |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| HU230031B1 (hu) * | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| CN103494796B (zh) * | 2013-09-30 | 2016-01-20 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
| CN104311608B (zh) * | 2014-10-28 | 2016-10-05 | 河南中烟工业有限责任公司 | 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用 |
| CN104370986B (zh) * | 2014-10-28 | 2017-07-04 | 河南中烟工业有限责任公司 | 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用 |
| CN105520918B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊 |
| CN105434395B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| CA2344407C (en) * | 1998-10-16 | 2007-01-09 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| PL365927A1 (en) * | 2000-11-30 | 2005-01-10 | Pfizer Products Inc. | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
-
2002
- 2002-01-28 US US10/058,903 patent/US7022678B2/en not_active Expired - Fee Related
- 2002-02-25 KR KR10-2003-7012714A patent/KR20040008146A/ko not_active Ceased
- 2002-02-25 AP APAP/P/2003/002873A patent/AP2003002873A0/en unknown
- 2002-02-25 HU HU0303956A patent/HUP0303956A2/hu unknown
- 2002-02-25 CN CNA028067509A patent/CN1511043A/zh active Pending
- 2002-02-25 OA OA1200300232A patent/OA12456A/en unknown
- 2002-02-25 IL IL15787902A patent/IL157879A0/xx unknown
- 2002-02-25 EE EEP200300480A patent/EE200300480A/xx unknown
- 2002-02-25 CA CA002440468A patent/CA2440468C/en not_active Expired - Fee Related
- 2002-02-25 CZ CZ20032547A patent/CZ20032547A3/cs unknown
- 2002-02-25 PL PL02369179A patent/PL369179A1/xx not_active Application Discontinuation
- 2002-02-25 EP EP02702614A patent/EP1377318A2/en not_active Withdrawn
- 2002-02-25 WO PCT/IB2002/000647 patent/WO2002078747A2/en not_active Ceased
- 2002-02-25 MX MXPA03007437A patent/MXPA03007437A/es active IP Right Grant
- 2002-02-25 EA EA200300954A patent/EA200300954A1/ru unknown
- 2002-02-25 JP JP2002577011A patent/JP2004524357A/ja active Pending
- 2002-02-25 SK SK1183-2003A patent/SK11832003A3/sk not_active Application Discontinuation
- 2002-02-25 BR BR0208439-2A patent/BR0208439A/pt not_active IP Right Cessation
- 2002-03-07 DO DO2002000356A patent/DOP2002000356A/es unknown
- 2002-03-19 GT GT200200051A patent/GT200200051A/es unknown
- 2002-03-22 SV SV2002000928A patent/SV2003000928A/es not_active Application Discontinuation
- 2002-03-27 PA PA20028542101A patent/PA8542101A1/es unknown
- 2002-03-27 PE PE2002000252A patent/PE20021016A1/es not_active Application Discontinuation
- 2002-03-27 UY UY27233A patent/UY27233A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101140A patent/AR033024A1/es unknown
- 2002-03-29 TN TNTNSN02038A patent/TNSN02038A1/fr unknown
-
2003
- 2003-08-14 IS IS6912A patent/IS6912A/is unknown
- 2003-08-21 EC EC2003004740A patent/ECSP034740A/es unknown
- 2003-08-25 ZA ZA200306608A patent/ZA200306608B/en unknown
- 2003-09-17 MA MA27315A patent/MA27004A1/fr unknown
- 2003-09-24 BG BG108193A patent/BG108193A/xx unknown
- 2003-09-29 NO NO20034348A patent/NO20034348L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2003000928A (es) | Conjugados de pregabalina-lactosa ref. pca513-01 | |
| HN1999000124A (es) | Derivados de pirazol substituido. | |
| DE50211204D1 (de) | Cannabis extrakten pharmazeutische zusammensetzung | |
| BRPI0110914B8 (pt) | 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica' | |
| EA200400481A1 (ru) | Применение флибансерина для лечения половых расстройств | |
| SV2003001107A (es) | Imidazotriazinas ref.lea 35368 | |
| ES2162319T3 (es) | Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer. | |
| HN2001000037A (es) | Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| BR0014652A (pt) | Fabricação de conjugados de agente terapêutico-poliglutamato | |
| BR0316438A (pt) | Uso de eritropoietina em doenças cardìacas | |
| BR0016467A (pt) | Lipopeptìdeos como agentes antibacterianos | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| UY26992A1 (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides | |
| BR0111892A (pt) | Bis-arilsulfonas | |
| BR9811086A (pt) | Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica | |
| EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
| BR0210013A (pt) | Gel oftálmico de pirenzepina | |
| NO20023551D0 (no) | Ibuprofen-inneholdende aktivt middel-preparat | |
| WO2003026563A3 (en) | Conjugated anti-psychotic drugs and uses thereof | |
| DE602004031208D1 (de) | Keratolytische zusammensetzung mit antiallergischen und entzündungshemmenden eigenschaften | |
| BRPI0507530A (pt) | preparação para liberação prolongada, agente para evitar ou tratar doença, processo para produzir a preparação para liberação prolongada, método para evitar ou tratar doença, e, uso da preparação para liberação prolongada | |
| BR0011578A (pt) | Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico | |
| AR030378A1 (es) | Empleo de triazintrion-sulfonas para la lucha contra la coccidiosis | |
| BR0009194A (pt) | Composição do resorcinol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |